488 related articles for article (PubMed ID: 19023702)
1. Three new potential ovarian cancer biomarkers detected in human urine with equalizer bead technology.
Petri AL; Simonsen AH; Yip TT; Hogdall E; Fung ET; Lundvall L; Hogdall C
Acta Obstet Gynecol Scand; 2009; 88(1):18-26. PubMed ID: 19023702
[TBL] [Abstract][Full Text] [Related]
2. The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass.
Moore RG; Brown AK; Miller MC; Skates S; Allard WJ; Verch T; Steinhoff M; Messerlian G; DiSilvestro P; Granai CO; Bast RC
Gynecol Oncol; 2008 Feb; 108(2):402-8. PubMed ID: 18061248
[TBL] [Abstract][Full Text] [Related]
3. Proteomic classification of pancreatic adenocarcinoma tissue using protein chip technology.
Scarlett CJ; Smith RC; Saxby A; Nielsen A; Samra JS; Wilson SR; Baxter RC
Gastroenterology; 2006 May; 130(6):1670-8. PubMed ID: 16697731
[TBL] [Abstract][Full Text] [Related]
4. [The values of serum human epididymis secretory protein 4 and CA(125) assay in the diagnosis of ovarian malignancy].
Dong L; Chang XH; Ye X; Zhu LR; Zhao Y; Tian L; Cheng HY; Li XP; Zhang H; Liao QP; Fu TY; Cheng YX; Cui H
Zhonghua Fu Chan Ke Za Zhi; 2008 Dec; 43(12):931-6. PubMed ID: 19134334
[TBL] [Abstract][Full Text] [Related]
5. Proteomic-based discovery and characterization of glycosylated eosinophil-derived neurotoxin and COOH-terminal osteopontin fragments for ovarian cancer in urine.
Ye B; Skates S; Mok SC; Horick NK; Rosenberg HF; Vitonis A; Edwards D; Sluss P; Han WK; Berkowitz RS; Cramer DW
Clin Cancer Res; 2006 Jan; 12(2):432-41. PubMed ID: 16428483
[TBL] [Abstract][Full Text] [Related]
6. Characterization of serum biomarkers for detection of early stage ovarian cancer.
Kozak KR; Su F; Whitelegge JP; Faull K; Reddy S; Farias-Eisner R
Proteomics; 2005 Nov; 5(17):4589-96. PubMed ID: 16237736
[TBL] [Abstract][Full Text] [Related]
7. Biomarker discovery for ovarian cancer using SELDI-TOF-MS.
Zhang H; Kong B; Qu X; Jia L; Deng B; Yang Q
Gynecol Oncol; 2006 Jul; 102(1):61-6. PubMed ID: 16403569
[TBL] [Abstract][Full Text] [Related]
8. Serum peptide/protein profiling by mass spectrometry provides diagnostic information independently of CA125 in women with an ovarian tumor.
Callesen AK; Madsen JS; Iachina M; Vach W; Kruse TA; Jensen ON; Mogensen O
Cancer Biomark; 2010; 6(2):73-82. PubMed ID: 20571233
[TBL] [Abstract][Full Text] [Related]
9. [Clinical value of serum CA19-9, CA125 and CP2 in mucinous ovarian tumor: a retrospective study of 273 patients].
Dong L; Cui H; Li XP; Sun LF; Chang XH; Liang XD; Zhu HL
Zhonghua Fu Chan Ke Za Zhi; 2008 Jan; 43(1):5-8. PubMed ID: 18366923
[TBL] [Abstract][Full Text] [Related]
10. [Analysis of serum biomarkers of ovarian epithelial cancers based on 2-DE DIGE and MALDI TOF/TOF].
Zhao Q; Duan W; Wu YM; Qian XH; Deng XH
Zhonghua Zhong Liu Za Zhi; 2008 Oct; 30(10):754-8. PubMed ID: 19173805
[TBL] [Abstract][Full Text] [Related]
11. Afamin and apolipoprotein A-IV: novel protein markers for ovarian cancer.
Dieplinger H; Ankerst DP; Burges A; Lenhard M; Lingenhel A; Fineder L; Buchner H; Stieber P
Cancer Epidemiol Biomarkers Prev; 2009 Apr; 18(4):1127-33. PubMed ID: 19336561
[TBL] [Abstract][Full Text] [Related]
12. Proteomic profiling of cholangiocarcinoma: diagnostic potential of SELDI-TOF MS in malignant bile duct stricture.
Scarlett CJ; Saxby AJ; Nielsen A; Bell C; Samra JS; Hugh T; Baxter RC; Smith RC
Hepatology; 2006 Sep; 44(3):658-66. PubMed ID: 16941699
[TBL] [Abstract][Full Text] [Related]
13. Protein profiling of post-prostatic massage urine specimens by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry to discriminate between prostate cancer and benign lesions.
Okamoto A; Yamamoto H; Imai A; Hatakeyama S; Iwabuchi I; Yoneyama T; Hashimoto Y; Koie T; Kamimura N; Mori K; Yamaya K; Ohyama C
Oncol Rep; 2009 Jan; 21(1):73-9. PubMed ID: 19082445
[TBL] [Abstract][Full Text] [Related]
14. Proteomic profiling identifies afamin as a potential biomarker for ovarian cancer.
Jackson D; Craven RA; Hutson RC; Graze I; Lueth P; Tonge RP; Hartley JL; Nickson JA; Rayner SJ; Johnston C; Dieplinger B; Hubalek M; Wilkinson N; Perren TJ; Kehoe S; Hall GD; Daxenbichler G; Dieplinger H; Selby PJ; Banks RE
Clin Cancer Res; 2007 Dec; 13(24):7370-9. PubMed ID: 18094419
[TBL] [Abstract][Full Text] [Related]
15. Significance of preoperative serum CA-125 levels in the prediction of lymph node metastasis in epithelial ovarian cancer.
Kim HS; Park NH; Chung HH; Kim JW; Song YS; Kang SB
Acta Obstet Gynecol Scand; 2008; 87(11):1136-42. PubMed ID: 18951217
[TBL] [Abstract][Full Text] [Related]
16. Accuracy of tissue polypeptide specific antigen (TPS) in the diagnosis of ovarian malignancy.
Padungsutt P; Thirapagawong C; Senapad S; Suphanit I
Anticancer Res; 2000; 20(2B):1291-5. PubMed ID: 10810437
[TBL] [Abstract][Full Text] [Related]
17. [Identification of two potential serum biomarkers for ovarian cancer and clinical validation thereof].
Wang Q; Zhang W; Li DR; Li L
Zhonghua Yi Xue Za Zhi; 2008 Apr; 88(15):1012-6. PubMed ID: 18754431
[TBL] [Abstract][Full Text] [Related]
18. Proteomic analysis and identification of new biomarkers and therapeutic targets for invasive ovarian cancer.
Jones MB; Krutzsch H; Shu H; Zhao Y; Liotta LA; Kohn EC; Petricoin EF
Proteomics; 2002 Jan; 2(1):76-84. PubMed ID: 11788994
[TBL] [Abstract][Full Text] [Related]
19. A novel proteomic biomarker panel as a diagnostic tool for patients with ovarian cancer.
Høgdall C; Fung ET; Christensen IJ; Nedergaard L; Engelholm SA; Petri AL; Risum S; Lundvall L; Yip C; Pedersen AT; Hartwell D; Lomas L; Høgdall EV
Gynecol Oncol; 2011 Nov; 123(2):308-13. PubMed ID: 21855971
[TBL] [Abstract][Full Text] [Related]
20. Using proteomic approaches to identify new biomarkers for detection and monitoring of ovarian cancer.
Kong F; Nicole White C; Xiao X; Feng Y; Xu C; He D; Zhang Z; Yu Y
Gynecol Oncol; 2006 Feb; 100(2):247-53. PubMed ID: 16229881
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
